Vendor Intelligence Report: Xingtai Pukelai Technology Co

Published 13 Jun 2026. 18-page investigative report on who is behind Xingtai Pukelai Technology Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 7 Finnrick lab tests, Xingtai Pukelai Technology Co records 5 pass / 2 fail, for a 71% overall pass rate, all on Retatrutide. The useful signal is narrow: identity and purity look comparatively solid, but the vendor's weakness is operational control. Repeated quantity misses and missing batch identifiers make the same Retatrutide record read much worse under stricter buyer assumptions than under a purity-first view.

This is not a broad endorsement of Pukelai's catalog. Finnrick has no supplied data for Tirzepatide, Semaglutide, BPC-157 or any other peptide, so the report treats Pukelai as a Retatrutide-only decision. For that product, the vendor is best understood as middle-tier: plausible material, weak fill discipline, poor traceability, and a label that should not be trusted as the milligram source of truth.

The counterparty file adds a separate diligence problem. Chinese registry data describes a newly incorporated, residential-address company with a general trade-style scope and foreign-trade sales hiring, not a verified peptide manufacturer. The supplied GlobalSources storefront was already unavailable during field collection, no official domain or social channel was identified, and directory, customs, forum and review sweeps produced little independent footprint.

The strongest non-lab hook is the Xingtai cluster context. Pukelai sits near a set of 2025-era Hebei peptide vendors whose B2B profiles use manufacturer/export-experience boilerplate that the records do not cleanly support. The full report separates what is proven from what remains open, including whether these sellers share owners, logistics or upstream suppliers.

Inside the full report:

  • Finnrick Retatrutide breakdown and methodology-divergence charts for the full dataset
  • Sample-level quantity-deviation and batch-ID analysis from seven Retatrutide tests
  • Yupao registry extract covering incorporation, legal representative, address and business scope
  • GlobalSources supplier-unavailable capture and channel-authenticity sweep across domains and directories
  • Xingtai cluster comparison using GlobalSources captures for Gemi, Lesda and Jiachuang
  • Sanctions, customs and name-confusion boundary checks using OpenSanctions, OFAC context and ImportYeti

Risk assessment

  • Retatrutide dosing-accuracy risk — high: Finnrick tracked only Retatrutide: 7 tests, 5 pass / 2 fail (76.75%); sample-level field notes report repeated quantity deviations, including a 15.7% underfill.
  • Manufacturer-status misrepresentation risk — high: Pukelai was encountered as a manufacturer-style supplier, but registry records show an April 25, 2025 residential-address entity with no peptide/pharma manufacturing scope.
  • Retatrutide traceability failure risk — medium: Field notes and Finnrick screenshots report batch IDs absent on 6 of 7 Retatrutide samples, weakening recall and contamination tracing.
  • Brand-verification and channel-authenticity risk — medium: No official domain or social channel was found, and the GlobalSources supplier page redirects to supplier unavailable.
  • Xingtai cluster-pattern risk — medium: Comparable 2025 Xingtai peptide vendors use contradictory boilerplate claims and some GlobalSources profiles carry buyer warnings; shared ownership/logistics remain unconfirmed.